This site is intended for healthcare professionals
CSU Learning Zone

Expert Opinion

Read time: 70 mins

CSU Expert Opinion

Watch a series of videos from key opinion leaders, providing invaluable knowledge and insights regarding Chronic Spontaneous Urticaria (CSU). Each month new videos will be added covering treatment goals, guidelines, omalizumab data, CSU case reports and more. Make sure you come back regularly over the next 12 months to stay up-to-date with the latest expert opinion.
Our two most recent topics are: Omalizumab – Are there any other treatment /access considerations? and The burden of CSU – a patient’s perspective.

Click your topic of choice below to hear the opinions of our experts.

What is urticaria and how do you assess the severity?

In the latest ASCIA and EAACI guidelines the classification of urticaria changed, and this has raised many questions with dermatologists about possible treatments and the disease itself. This range of videos explores the current description of chronic spontaneous urticaria (formally idiopathic urticaria) in practice at the moment, while also touching on the differentiation between autoimmune and physical urticaria.

With a concise overview of symptoms and pathogenesis, it provides invaluable background to the changing treatment landscape driven by the PCB approval of omalizumab. This has enabled a previously frustrating condition to become more effectively treated. 


Register free for full access to

What are the guidelines, treatment goals and recommendations for Chronic Spontaneous Urticaria?

Find out how the EAACI/GA2LEN/EDF/WAO guidelines have changed in the latest 2017 revision and how this differs from the current 2015 ASCIA guidelines. Where does omalizumab fit into the treatment algorithm and what treatment goals should you be aiming to achieve? 

Are specific tests or work-up necessary when treating with omalizumab? You can also discover more about recommendations for diagnosis including which approaches to use for children, pregnant women and during lactation.


Register free for full access to

What is omalizumab?

Although it is over two decades since the discovery of omalizumab, its mechanism of action is still not fully understood. What is known is that its efficacy can’t solely be attributed to its anti-immunoglobulin-E binding activity. Many possibilities have been postulated and uncovering these has the potential to help elucidate the complex multifactorial pathways of CSU. 

Learn more about the mechanism of action of omalizumab, it’s role in treatment and its impact on patients who have suffered with chronic urticaria for years without a viable solution.


Register free for full access to

Omalizumab – Are there safety considerations?


What is the risk of anaphylaxis when administering omalizumab in patients with CSU? Is there guidance for monitoring patients after injections? 


Register free for full access to

Omalizumab – Are there any other treatment / access considerations? 

Omalizumab can provide significant benefits to CSU patients, but access is subject to tight restrictions under the Highly Specialised Drugs Program. 


To access PBS funded omalizumab for the treatment of CSU, you and your patient must satisfy an extensive list of criteria and the application process can present certain challenges. What are these criteria and how can the challenges associated with the application process be overcome? 


Register free for full access to

The burden of CSU – a patient’s perspective 


What impact does CSU have on the lives of patients? 


Register free for full access to


Developed by EPG Health for Medthority in collaboration with Novartis Pharma AG, with some content provided by Novartis Pharma AG. An unrestricted educational grant was provided from Novartis Pharma AG for the development of the e-Learning module within this Learning Zone (Novartis were not involved in the content or development of these modules). Developed by EPG Health for Medthority in collaboration with J. Uriach y Compañía S.A, with some content provided by J. Uriach y Compañía S.A.